|Awarded On||February 21, 2018|
|Title||A Novel Dual Suppressor of Cancer Bone Metastasis|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas Southwestern Medical Center|
|Principal Investigator/Program Director||Yihong Wan|
|Cancer Sites||Bone, Breast|
Current cancer research often focuses on the primary tumors alone. However, most cancer mortality relates to metastasis, a complex process involving not only cancer cells but also their microenvironment in the host tissues. Bone metastasis is a frequent, debilitating and deadly consequence of many cancers. It affects >70% of patients with advanced breast cancer. This leads to bone pain, fractures, life-threatening hypercalcemia, limited mobility and increased mortality. Current bone-met drugs cannot improve patient survival, and thus bone met remains incurable. Since late 2014, three PARP inhibitors have been approved by the FDA for treating ovarian cancer. Several PARP inhibitors are als...